Who are TRUVADA™ or EPZICOM™/KIVEXA™'s main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): JULUCA, DOR/DTG/3TC, First-line Antiretroviral Therapy, Standard Triple, Adefor dipivoxil, emtricitabine, darunavir/cobicistat, maraviroc.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/truvada-or-epzicom-kivexa.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

TRUVADA™ or EPZICOM™/KIVEXA™ — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

TRUVADA™ or EPZICOM™/KIVEXA™ (TRUVADA™ or EPZICOM™/KIVEXA™) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: NRTI. Area: Infectious Disease.

phase 3 NRTI Reverse transcriptase Infectious Disease Small molecule Live · refreshed every 30 min

Target snapshot

TRUVADA™ or EPZICOM™/KIVEXA™ (TRUVADA™ or EPZICOM™/KIVEXA™) — Merck Sharp & Dohme LLC. TRUVADA and EPZICOM/KIVEXA are antiretroviral medications used to treat HIV-1 infection by inhibiting viral replication.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
TRUVADA™ or EPZICOM™/KIVEXA™ TARGET	TRUVADA™ or EPZICOM™/KIVEXA™	Merck Sharp & Dohme LLC	phase 3	NRTI	Reverse transcriptase
JULUCA	JULUCA	ViiV Healthcare	marketed	Antiretroviral combination (integrase inhibitor + NNRTI)	HIV integrase and HIV reverse transcriptase
DOR/DTG/3TC	DOR/DTG/3TC	Insel Gruppe AG, University Hospital Bern	marketed	Antiretroviral combination (NNRTI + INSTI + NRTI)	HIV reverse transcriptase, HIV integrase
First-line Antiretroviral Therapy	First-line Antiretroviral Therapy	UPECLIN HC FM Botucatu Unesp	marketed	Antiretroviral combination therapy (NRTI/NNRTI/PI/INSTI)	HIV reverse transcriptase, HIV protease, HIV integrase (depending on regimen components)
Standard Triple	Standard Triple	University of Alberta	marketed	Antiretroviral combination therapy	HIV reverse transcriptase, HIV protease (depending on formulation)
Adefor dipivoxil	Adefor dipivoxil	GlaxoSmithKline	marketed	Nucleotide reverse transcriptase inhibitor	Hepatitis B virus reverse transcriptase
emtricitabine, darunavir/cobicistat, maraviroc	emtricitabine, darunavir/cobicistat, maraviroc	Giovanni Di Perri	marketed	Antiretroviral combination (NRTI + PI + pharmacokinetic booster + CCR5 antagonist)	HIV reverse transcriptase, HIV protease, CYP3A4, CCR5 co-receptor

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (NRTI class)

Germans Trias i Pujol Hospital · 1 drug in this class
Merck Sharp & Dohme LLC · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). TRUVADA™ or EPZICOM™/KIVEXA™ — Competitive Intelligence Brief. https://druglandscape.com/ci/truvada-or-epzicom-kivexa. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab